[HTML][HTML] Diagnosis and treatment of therapy-related acute myeloid leukemia
SA Strickland, N Vey - Critical Reviews in Oncology/Hematology, 2022 - Elsevier
Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …
[HTML][HTML] New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
AH Matthews, AE Perl, SM Luger, AW Loren… - Blood …, 2022 - ashpublications.org
CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188
patients (median age 65 years, range 26–80) treated for therapy-related acute myeloid …
patients (median age 65 years, range 26–80) treated for therapy-related acute myeloid …
What to use to treat AML: The role of emerging therapies
F Thol - Hematology, 2021 - ashpublications.org
The development and approval of novel substances have resulted in substantial
improvements in the treatment of acute myeloid leukemia (AML). In the current era of novel …
improvements in the treatment of acute myeloid leukemia (AML). In the current era of novel …
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
R Devillier, E Forcade, A Garnier… - Blood …, 2022 - ashpublications.org
The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients
with acute myeloid leukemia (AML) aged> 60 years remains a matter of debate, notably …
with acute myeloid leukemia (AML) aged> 60 years remains a matter of debate, notably …
[HTML][HTML] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021
I Urbino, C Secreto, M Olivi, V Apolito, S D'Ardia… - Cancers, 2021 - mdpi.com
Simple Summary The better understanding of disease biology, the availability of new
effective drugs and the increased awareness of patients' heterogeneity in terms of fitness …
effective drugs and the increased awareness of patients' heterogeneity in terms of fitness …
Refining AML treatment: the role of genetics in response and resistance evaluation to new agents
Simple Summary Acute myeloid leukemia (AML) is an aggressive cancer of the
hematopoietic system. At present, we know that AML is heterogeneous and varies from one …
hematopoietic system. At present, we know that AML is heterogeneous and varies from one …
Measurable residual disease in high-risk acute myeloid leukemia
T Cluzeau, RM Lemoli, J McCloskey, T Cooper - Cancers, 2022 - mdpi.com
Simple Summary Assessment of measurable residual disease (MRD) identifies small
numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment …
numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment …